These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 29697005)

  • 1. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure.
    Ludmir EB; Milgrom SA; Pinnix CC; Gunther JR; Westin J; Oki Y; Fayad LE; Medeiros LJ; Dabaja BS; Nastoupil LJ
    Leuk Lymphoma; 2018 Dec; 59(12):2896-2903. PubMed ID: 29697005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary breast diffuse large B-cell lymphoma characterized by CNS relapse and successful hematopoietic stem cell transplantation salvage therapy.
    Chan CY; Ou CW; Chang H; Kuo MC; Lin TL; Hung YS; Wu JH; Shih LY; Kao HW
    J Formos Med Assoc; 2024 Oct; 123(10):1078-1086. PubMed ID: 38296697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
    Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
    Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous but not intrathecal central nervous system-directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Mannisto S; Vähämurto P; Pollari M; Clausen MR; Jyrkkiö S; Kellokumpu-Lehtinen PL; Kovanen P; Karjalainen-Lindsberg ML; d'Amore F; Leppä S
    Eur J Cancer; 2019 Jul; 115():27-36. PubMed ID: 31082690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
    Ryan GF; Roos DR; Seymour JF
    Clin Lymphoma Myeloma; 2006 Jan; 6(4):337-41. PubMed ID: 16507213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of bulky mass and residual tumor-Treated with or without consolidative radiotherapy-To the risk of relapse in DLBCL patients.
    Tokola S; Kuitunen H; Turpeenniemi-Hujanen T; Kuittinen O
    Cancer Med; 2020 Mar; 9(6):1966-1977. PubMed ID: 31967739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
    Kansara R
    Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Hodgkin lymphoma of the breast.
    Ganjoo K; Advani R; Mariappan MR; McMillan A; Horning S
    Cancer; 2007 Jul; 110(1):25-30. PubMed ID: 17541937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.
    Ryan G; Martinelli G; Kuper-Hommel M; Tsang R; Pruneri G; Yuen K; Roos D; Lennard A; Devizzi L; Crabb S; Hossfeld D; Pratt G; Dell'Olio M; Choo SP; Bociek RG; Radford J; Lade S; Gianni AM; Zucca E; Cavalli F; Seymour JF;
    Ann Oncol; 2008 Feb; 19(2):233-41. PubMed ID: 17932394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.
    Hu S; Song Y; Sun X; Su L; Zhang W; Jia J; Bai O; Yang S; Liang R; Li X; Zhang H; Gao Y; Zhang W; Xiao X; Bao H; Wang N; Ren H; Cen X; Yang S; Zhao Y; Wang Y; Wang Y; Liu A; Wang J; Shi Y; Yuan M; Li Y; He X
    Cancer Sci; 2018 Dec; 109(12):3943-3952. PubMed ID: 30302857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Primary breast lymphoma--a report of 27 cases with literature review].
    Cao YB; Wang SS; Huang HQ; Xu GC; He YJ; Guan ZZ; Lin TY
    Ai Zheng; 2007 Jan; 26(1):84-9. PubMed ID: 17222374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
    Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
    J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Kridel R; Telio D; Villa D; Sehn LH; Gerrie AS; Shenkier T; Klasa R; Slack GW; Tan K; Gascoyne RD; Connors JM; Savage KJ
    Br J Haematol; 2017 Jan; 176(2):210-221. PubMed ID: 27739058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
    Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
    Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.
    Tao R; Allen PK; Rodriguez A; Shihadeh F; Pinnix CC; Arzu I; Reed VK; Oki Y; Westin JR; Fayad LE; Medeiros LJ; Dabaja B
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):122-9. PubMed ID: 25754633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
    Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution.
    Fukuhara S; Watanabe T; Munakata W; Mori M; Maruyama D; Kim SW; Kobayashi Y; Taniguchi H; Maeshima AM; Tanosaki R; Matsuno Y; Tobinai K
    Eur J Haematol; 2011 Nov; 87(5):434-40. PubMed ID: 21740461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.